COMMUNIQUÉS West-GlobeNewswire

IntelGenx to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
25/04/2019
SAINT LAURENT, Quebec, April 25, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that its Executive Vice-President and Chief [...]
miRagen Therapeutics to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8th
25/04/2019
BOULDER, Colo., April 25, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a [...]
Cyclerion to Host Corporate Overview Call on May 13, 2019
25/04/2019
CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for [...]
CMS’ New Value-Based Payment Program is a Catalyst for Tabula Rasa HealthCare
25/04/2019
Under new policy changes, more patients and providers will benefit from TRHC’s medication safety technology, resulting in improved quality of care and patient outcomes MOORESTOWN, N.J., April 25, 2019 (GLOBE NEWSWIRE [...]
Lexington Biosciences to Consolidate its Common Shares
25/04/2019
VANCOUVER, British Columbia, April 25, 2019 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”) announces that effective at the opening of markets on April 26, 2019, [...]
North Bud Farms Simplifies Trading in the U.S. Market with DTC Eligibility
25/04/2019
TORONTO, April 25, 2019 (GLOBE NEWSWIRE) -- North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) ("NORTHBUD" or the "Company") is pleased to announce it has received approval from The Depository Trust Company (“DTC”) of New [...]
Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Thursday, May 2, 2019
25/04/2019
CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic [...]
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update
25/04/2019
CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and [...]
Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
25/04/2019
LONDON, April 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it [...]
Clearside Biomedical to Report First Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, May 8, 2019
25/04/2019
ALPHARETTA, Ga., April 25, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]
Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2019
25/04/2019
Press Release 25 April 2019 Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2019 At the Annual General Meeting (the "AGM") of Immunicum AB (publ), reg. no 556629-1786, (the "Company"), on [...]
Optinose to Report First Quarter 2019 Financial Results and Corporate Updates on May 9, 2019
25/04/2019
Conference Call and Webcast Scheduled for Thursday, May 9 at 8:00 a.m. Eastern Time YARDLEY, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, [...]
Athenex, Inc. to Report First Quarter 2019 Earnings Results on May 9, 2019
25/04/2019
BUFFALO, N.Y., April 25, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
NeuroMetrix Reports Q1 2019 Financial Results
25/04/2019
WALTHAM, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended March 31, 2019. The Company develops and markets novel [...]
Amicus Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
25/04/2019
CRANBURY, N.J., April 25, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 8:30 a.m. ET to [...]
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis
25/04/2019
WAYNE, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that it has [...]
Lexicon Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 1, 2019
25/04/2019
THE WOODLANDS, Texas, April 25, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2019 financial results on Wednesday, May 1, 2019 before market opens. Management will [...]
Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results
25/04/2019
NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, [...]
Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline
25/04/2019
-Merger creates a publicly-traded clinical stage immuno-oncology company developing treatments for advanced cancers including aggressive brain tumors, pancreatic cancer, and melanoma -Phase 2 clinical data on lead [...]

Pages